Journal of Clinical Oncology
Articles in this Issue
Clonal hematopoiesis of indeterminate potential mutations in neuroendocrine tumor patients: Cluster analysis and application of risk scores.
e16354 Background: Clonal Hematopoiesis of Indeterminate Potential (CHIP) mutations are associated with an increased risk of myeloid malignancies and may...
Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial.
8006 Background: Despite improved efficacy when adding 1L PD-(L)1 inhibitors to platinum-based chemotherapy for ES-SCLC, long-term survival remains limite...
Avelumab maintenance therapy for metastatic urothelial carcinoma: Efficacy analysis and sequential therapies from a multicentric oncology network.
e16571 Background: Metastatic urothelial cancer (MUC) is a challenging condition with high mortality rates and generally poor prognosis. Avelumab is an im...
Clinical determinants and outcomes of hypothyroidism in immune checkpoint inhibitor (ICI) therapy.
e14623 Background: Immune checkpoint inhibitors (ICIs) are transformative for their efficacy in cancer treatment; however, they are associated with thyroi...
Efficacy of neoadjuvant immunotherapy in head and neck squamous carcinoma (HNSCC): A systematic review and meta-analysis.
e18012 Background: Head and neck squamous cell carcinoma (HNSCC) is a significant global health burden with limited treatment options in advanced stages....
Association of hospitalized metastatic cancers of the lip, oral cavity, and pharynx, with burden of illness, and cachexia.
e18043 Background: Recent studies have suggested that cancers of the lip, oral cavity and pharynx (CLOP) patients face high clinical and financial challen...
Intermittent PARP inhibitor regimen in ovarian cancer (IPIROC): A proof-of-concept exploratory pragmatic study (IPIROC#02) using generic rucaparib with pharmacodynamic assessment.
e17597 Background: Affordability/toxicity of PARP inhibitors (PARPi) for ovarian cancer treatment is an unmet need in women with anemia/low BMI in LMICs....
Open-source modular AI coupled with agentic AI for comprehensive breast cancer note generation and guideline-directed treatment comparison.
e13685 Background: Generative Artificial Intelligence (GenAI) has demonstrated promise as a clinical decision support tool. Previous studies utilized clos...
Initial safety and efficacy of PDL1V (PF-08046054), a vedotin-based ADC targeting PD-L1, in combination with pembrolizumab in patients with recurrent or metastatic (R/M) HNSCC.
6033 Background: PDL1V is a novel investigational antibody-drug conjugate that delivers monomethyl auristatin E (MMAE) to cells that express programmed ce...
Survival outcomes for stage II and III medullary renal cancer patients treated with perioperative chemotherapy: A retrospective analysis.
e16526 Background: Medullary renal cancer (MRC) is a rare, aggressive histological subtype of renal carcinoma associated with poor prognosis. The potentia...
Clinical outcomes of patients with or without DNA repair pathway alterations by treatment type: The MD Anderson Cancer Center IMPACT 2 study.
2660 Background: DNA repair deficiency is common among tumors, and emerging data suggest that genomic instability is associated with response to immuno-on...
Outcomes for patients with platinum-sensitive recurrent ovarian cancer treated with prolonged PARP inhibitor therapy.
e17607 Background: PARP inhibitors (PARPi) can be an effective tool for treatment and maintenance in platinum-sensitive recurrent epithelial ovarian cance...
FluBu2 and FluMel with and without PTCY: Comparative effectiveness and safety in allogeneic stem transplantation for adults with myeloid malignancies.
e18563 Background: Reduced-intensity conditioning regimens, such as fludarabine with 2 days of busulfan (FluBu2) or fludarabine with melphalan (FluMel), a...
Phase I/Ib study of concurrent intravenous (IV) and intrathecal (IT) nivolumab (N) and relatlimab (R) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD).
TPS9592 Background: Pts with LMD face dismal prognosis, with median overall survival (OS) measured in months. We previously reported the safety and effica...
Gentian violet compared with methylene blue for sentinel lymph node biopsy in breast cancer: A retrospective analysis from a resource-limited setting.
1604 Background: Sentinel lymph node biopsy (SLNB) minimizes morbidity in breast cancer surgeries compared to axillary lymph node dissection. Standard tra...
Biologically interpretable pathomics-driven transformer model with self-supervised training for outcome prediction of immunotherapy in non-small cell lung cancer.
1577 Background: Only a subset of non-small cell lung cancer (NSCLC) patients experiences durable benefit from immune checkpoint inhibitors (ICIs), and pr...
Enhanced efficacy of inavolisib combined with anti-PD-1 or anti-HER2 antibody in treating brain metastases from breast cancer.
1108 Background: The PI3K/AKT/mTOR signaling pathway is a crucial regulatory pathway involved in cell proliferation, survival, migration, and metabolism....
Effect of elevated expression of <i>LILRB4</i> and <i>TSC22D3</i> on survival in lung cancer.
2633 Background: HER2/neu mutations or amplifications, present in up to 23% of non-small cell lung cancers (NSCLCs), activate STAT3, promoting inflammatio...
Quantifying patient preferences for bacillus Calmette-Guérin (BCG) and PD-(L)1 inhibitors in high-risk non-muscle invasive bladder cancer (NMIBC): A discrete choice experiment.
4579 Background: Intravesical Bacillus Calmette-Guerin (BCG) induction + maintenance (I+M) is the standard of care for high-risk NMIBC. Disease recurrence...
Functional role of GLI2 in cancer-associated fibroblasts for modulation of the fibrotic tumor microenvironment within pancreatic cancer.
4155 Background: The tumor microenvironment (TME) that surrounds pancreatic ductal adenocarcinoma (PDAC) is a multi-faceted and dynamic ecosystem in which...
Racial disparities in clinical outcomes of early-stage triple-negative breast cancer treated with neoadjuvant chemoimmunotherapy: Insights from the NCDB.
602 Background: Triple-negative breast cancer (TNBC) is an aggressive breast cancer (BC) subtype, and Black patients (pts) with TNBC have worse survival o...
Implications of homologous recombination repair pathway mutations on the immune microenvironment in gastric cancer.
e16019 Background: Homologous recombination repair (HRR), a key pathway in DNA damage response (DDR), is linked to the efficacy of platinum-based chemothe...
ABLE-32: A randomized, controlled, phase 3b clinical trial of nadofaragene firadenovec-vncg versus observation in patients with intermediate-risk non–muscle-invasive bladder cancer.
TPS4632 Background: There is currently no Food and Drug Administration (FDA)-approved treatment for intermediate-risk non–muscle-invasive bladder cancer (...
BCI biomarker performance in premenopausal women with breast cancer.
e12506 Background: Breast Cancer Index (BCI) is a gene expression biomarker that evaluates cell proliferation and estrogen signaling to guide extended end...
Effect of statins on the mortality of long-term survivors of nasopharyngeal carcinoma.
e18084 Background: Despite the significant increase in five-year overall survival (OS) rate of patients with nasopharyngeal cancer (NPC) over the past few...